miR-1 and miR-133b expression in canine osteosarcoma

被引：16

作者：

Leonardo, Leonardi ^{[1
]}

Laura, Pazzaglia ^{[2
]}

Serena, Benassi Maria ^{[2
]}

机构：

[1] Univ Perugia, Dept Vet Med, Via San Costanza 4, I-06126 Perugia, Italy

[2] Rizzoii Orthopaed Inst, Lab Expt Oncol, Via Barbiano 1-10, I-40136 Bologna, Italy

来源：

RESEARCH IN VETERINARY SCIENCE | 2018年 / 117卷

关键词：

MicroRNA; Canine osteosarcoma; Gene target; Immunohistochemistry; IN-VIVO; CELL-LINES; MET; TUMORS; MICRORNAS; SIGNATURE; IDENTIFICATION; DYSREGULATION; DIAGNOSIS; SURVIVAL;

D O I：

10.1016/j.rvsc.2017.12.002

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

Osteosarcoma (OS) is the most common primary malignant bone tumor in dogs and it is reported to represent 80-85% of primitive bone tumors and 3-4% of all canine tumors. Canine OS is highly comparable to human OS since it is characterized by similar genetic, biologic and clinical pathological features. MicroRNAs (miRNAs) are small non-coding RNA segments controlling post-transcriptional gene expression whose altered regulation has been described in different malignant tumors. In this study we analyzed the expression of two miRNAs with an important role in regulation of osteogenesis and tumor cell proliferation in order to define their role in canine OS development. A lower expression of miR-1 and miR-133b was seen in tumors when compared with normal bone associated to a higher expression of two target genes, respectively MET and MCL1. Accordingly, MET and MCL11 proteins presented a moderate to strong immunostaining in more than 50% of tumor samples. Our results, although obtained in a small series of cases, confirming the high molecular homology with human OS suggesting a potential role of miR-1 and miR-133b as biomarkers for canine OS treatment.

引用

页码：133 / 137

页数：5

共 36 条

[1] Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis:: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412 [J].